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The Distal and Proximal Regulatory Regions of the
Involucrin Gene Promoter have Distinct Functions
and Are Required for In Vivo Involucrin Expression
James F. Crish1, Ramamurthy Gopalakrishnan1, Frederic Bone1, Anita C. Gilliam2 and
Richard L. Eckert1,2,3,4,5
Involucrin is a marker of human keratinocyte differentiation. Previous studies show that the human involucrin
gene promoter has two distinct regulatory regions – the proximal regulatory region (PRR) and the distal
regulatory region (DRR). To study the role of these regions in vivo, we have constructed human involucrin
promoter transgenic mice and monitored the impact of specific promoter mutations on involucrin gene
expression. In this study, we monitor the impact of specific mutations on expression in a range of surface
epithelia. We begin by confirming previous observations made in footpad epidermis by showing that the full-
length involucrin promoter drives differentiation-appropriate expression in other surface epithelia, including
epidermis, cervix, and esophagus. We further show that mutation of the activator protein AP1-5 site in the DRR
completely eliminates transgene expression in all of these tissues. In contrast, mutation of the DRR Sp1 site
reduces overall expression, but does not alter the differentiation dependence. Additional studies identify a DRR
immediate suprabasal element (ISE). Deletion of the ISE results in a loss of transgene expression in the
immediate suprabasal layers. Our studies also indicate that the PRR is important for appropriate transgene
expression. Mutation of a PRR C/EBP (CCAAT enhancer binding protein) transcription factor binding site results
in patchy/discontinuous expression. These studies suggest that AP1, Sp1, and C/EBP transcription factors are
required for appropriate differentiation-dependent involucrin expression, and that the mechanism of
regulation is similar in most surface epithelia.
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INTRODUCTION
The epidermis is a differentiating system in which basal
proliferative cells undergo discrete rounds of proliferation.
The daughter cells from this division undergo profound
morphology changes as they proceed through the differentia-
tion process (Alonso and Fuchs, 2003). The ultimate fate of
these cells is to be lost from the body surface after performing
their protective function. These morphological changes are
driven by changes in gene expression. During this process, a
specific set of differentiation-appropriate genes are turned on
as part of the differentiation program. Several of these genes
encode proteins that are used to assemble the cornified
envelope. Involucrin is a cornified envelope precursor
protein (Rice and Green, 1979; Green, 1980; Watt and
Green, 1981; Etoh et al., 1986; Yaffe et al., 1992, 1993;
Eckert et al., 1993; Steinert and Marekov, 1997). Involucrin is
not expressed in basal cells, but expression ensues in the
immediate suprabasal layer (spinous layer) and is maintained
throughout the granular layer. As such, involucrin is
considered an early marker of the differentiation process. A
major goal of our effort is to understand the mechanisms that
regulate differentiation-dependent gene expression of invo-
lucrin as a model for epidermal gene regulation.
Previous studies identified two segments within the human
involucrin (hINV) promoter that are required for optimal
expression in cultured human epidermal keratinocytes
(Welter et al., 1995; Banks et al., 1998; Efimova et al.,
1998; Agarwal et al., 1999). These elements, called the distal
regulatory region (DRR) and the proximal regulatory region
(PRR), are required for optimal expression in cultured cells
(Welter et al., 1995). The DRR contains an activator protein
(AP1 site, AP1-5, and an adjacent Sp1 site that have been
implicated as being required for expression in footpad
epidermis (Welter et al., 1995; Banks et al., 1998; Crish
et al., 1998). The PRR contains CCAAT enhancer binding
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protein (C/EBP) and AP1 (AP1-1) sites that are required for
optimal expression in cultured human epidermal keratino-
cytes (Welter et al., 1995; Efimova et al., 1998; Agarwal
et al., 1999). Transgenic studies indicate a role for the AP1-5
site in epidermis, as mutation of this site results in absence of
expression (Crish et al., 1993, 1998, 2002). In the present
report, we describe transgenic mouse studies that further
define the role of these elements. In particular, we monitor
the effects of altering the DRR and PRR sites on expression in
a range of surface epithelia. We confirm an important role for
the DRR AP1-5 site and Sp1 sites. Our studies further indicate
that a DNA sequence element located in the DRR segment,
the immediate suprabasal element (ISE), is required for
appropriate expression. In addition, the PRR C/EBP factor
binding site is also required for appropriate expression.
Finally, our studies suggest that hINV expression requires
similar cis-acting DNA regulatory elements in a range of
surface epithelia. This suggests that common mechanisms
regulate involucrin expression in diverse epithelia.
RESULTS
The hINV DRR AP1-5 site is required for expression in diverse
epithelia
We began by analyzing the expression of the full-length hINV
transgene, hINV H6B. Animals that harbor the hINV H6B
transgene were created and expression was analyzed by
immunoblot and immunohistology. The structure of the H6B
transgene is shown in Figure 1a. As shown in Figure 1b, hINV
immunoreactive material is detected in the footpad, epider-
mis, and esophagus of hINV H6B transgenic mice. Staining of
sections with anti-hINV reveals an absence of hINV protein
expression in the basal layer (arrow) of footpad, cervix,
epidermis, and esophagus. However, strong expression is
observed in the suprabasal layers in each tissue. As expected,
replacing the rabbit anti-hINV antibody with a rabbit anti-IgG
as primary antibody results in an absence of detectable
staining, demonstrating specificity of the reagents. In addi-
tion, staining is not observed in the underlying connective
tissue layer in any tissue, indicating that expression is
epithelial-specific. Staining of non-transgenic mice reveals
an absence of staining with the hINV-specific antibody (not
shown) (Crish et al., 1998, 2002). Figure 1c shows that
mutation of the AP1-5 site in H6B(AP1-5mm) results in a
complete loss of expression in all epithelia, as confirmed by
immunoblot and immunohistology. These studies confirm
our previous reported findings in footpad epidermis (Crish
et al., 1993, 1998, 2002) and show that the AP1-5 site has an
important role in several surface epithelia.
The isolated DRR directs appropriate expression in multiple
epithelia
Previous cell culture studies implicate the AP1-5 and Sp1
sites within the DRR as being important for regulation (Welter
et al., 1995; Banks et al., 1998, 1999; Efimova et al., 1998;
Bikle et al., 2002). To examine the role of these elements in
greater detail, we cloned the DRR immediately upstream of
the hINV basal promoter to create DRR-P3.4B (Figure 2a).
We have previously shown that the basal promoter transgene,
P3.4B, does not drive expression in mice (Crish et al., 1998,
2002) (see Figure 3b). As shown in Figure 2b, linking the
isolated DRR to the hINV minimal promoter drives normal
differentiation-appropriate expression. Mutation of the
AP1-5 site, in the context of the isolated DRR element in
DRR-P3.4B(AP1-5mm), results in a complete loss of hINV
expression in all tissues (Figure 2c). We also mutated the
Sp1 site, located immediate downstream of the AP1-5 site
(Banks et al., 1998, 1999), to create DRR-P3.4B(Sp1m). As
shown in Figure 2d, mutation of the Sp1 site results in a
reduction in hINV expression, as evidenced by the decreased
hINV level relative to the b-actin (see immunoblot). How-
ever, although transgene expression level is reduced, appro-
priate suprabasal expression is maintained (Figure 2d).
Given the importance of the AP1-5 and Sp1 sites within
the DRR, we examined additional DRR modifications. These
constructs are shown in Figure 3a. Analysis of these
transgenic mice reveals that constructs including nucleotides
2,473/1,993 and 2,473/2,043 produce expression
patterns identical to those observed for the complete DRR
(nucleotides 2,473/1,953). In contrast, the DRR-
P3.4B(2,473/2,097) transgene, which lacks the segment
immediately downstream of the AP1-5/Sp1 sites, is expressed
at low levels and expression is confined to the high
suprabasal layers (ie absent in the immediate suprabasal
layers) (Figure 3b). A transgene, DRR-P3.4B(2,140/2,088),
encoding only the 52-nucleotide segment containing the
AP1-5 and Sp1 sites, drives expression in a manner similar to
that observed for DRR-P3.4B(2,473/2,097). Taken to-
gether, these results indicate that sequence elements within
nucleotides 2,097/2,043 are required, in conjunction
with the AP1-5/Sp1 sites, for appropriate differentiation-
dependent expression. In addition, a transgene containing the
isolated downstream site(s), DRR-P3.4B(2,097/1,950),
does not drive transcription in any tissue. The minimal
promoter transgene, P3.4B, does not drive involucrin
expression (Crish et al., 2000).
To compare the relative level of transgene expression, we
immunoblotted extracts of epidermis from individual trans-
genic lines using anti-hINV (Figure 4). In this experiment, as
in all other experiments in this paper, all lines tested were of
the F1 or subsequent generation, and transgene expression
was observed to be maintained in each generation (not
shown). As expected, owing to differences in integration site
in the murine host genome, transgene expression is variable
among individual lines for each construct. However, several
general trends are apparent. First, mutation of the AP1-5 site,
in the context of the full-length promoter or in the context of
the DRR, uniformly results in a complete loss of transgene
expression – in six hINV H6B(AP1-5mm) lines and seven
DRR-P3.4B(AP1-5mm) lines. Second, mutation of the Sp1 site
results in a consistent partial reduction in transgene expres-
sion – four of five DRR-P3.4B(Sp1m) lines (Figure 4a). Third,
trimming of the DRR results in a reduction in expression level
– four DRR-P3.4B(2,473/2,097) and three DRR-
P3.4B(2,140/2,088) lines (Figure 4b). Finally, no expres-
sion is observed in six DRR-P3.4B(2,097/1,950) and in six
P3.4B lines.
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Figure 1. The AP1-5 site is essential for expression in surface epithelia. (a) hINV transgene structure. For each schematic, the closed box indicates the
involucrin structural gene, which includes two exons separated by an intron (Eckert and Green, 1986), and the arrow indicates the transcription start site and the
direction of transcription. The promoter upstream regulatory region is shown by the black line and is numbered in nucleotides upstream of the transcription start
site. The PRR (nucleotides 241/7) is indicated by the blue box adjacent to the transcription start site. Shown are the C/EBP and AP1-1 sites within the PRR.
The DRR (nucleotides 2,473/1,953), which contains the AP1-5 and Sp1 sites, is indicated by the upstream blue box. The AP1-5 site mutation, AP1-5mm,
converts the AP1-5 site from 50-TGAGTCAG to 50-AGCTCCAG (altered nucleotides underlined) (Welter et al., 1995). The mutated AP1 site is rendered non-
functional (Welter et al., 1995). (b, c) Extracts from footpad, epidermal, and esophageal epithelia were prepared in sample buffer and equivalent amounts of
protein (20 mg/lane) were electrophoresed on the same gel, transferred to nitrocellulose, and incubated with rabbit anti-hINV. The blot was then stripped and
reused for detection of b-actin level. Antibody binding was detected by addition of appropriate secondary antibody and visualized using chemiluminescent
detection reagent. For immunohistology, sections were prepared and hINV expression was detected using rabbit anti-hINV followed by horseradish peroxidase-
conjugated goat anti-rabbit IgG. The footpad (FP), cervical (CX), epidermal (EPI), and esophageal (ESO) epithelia are defined by brackets. The arrows indicate the
basal layer of each epithelium. For the set of sections to the right in (b), anti-hINV primary antibody was substituted with rabbit anti-IgG. Secondary antibody
addition and visualization are as indicated for the other sections. Similar results were observed in each of eight independent transgenic lines for each construct.
The cervix was not assayed by immunoblot because the tissue is limiting.
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Figure 2. Role of the DRR AP1-5 and Sp1 sites. (a) hINV transgene structure. The hINV H6B transgene is described in the legend to Figure 1. The other
transgenes encode the DRR segment linked directly to the hINV minimal promoter construct (hINV P3.4B). The dashed line indicates the point of fusion. The
P3.4B minimal promoter transgene does not drive expression in any tissue (see Figure 3b) (Crish et al., 1998, 2002). (b,c) The AP1-5 site mutation, AP1-5mm,
converts the AP1-5 site from 50-TGAGTCAG to 50-AGCTCCAG (altered nucleotides underlined) (Welter et al., 1995). (d) The Sp1 site, 50-GGGCGGG, is mutated
to 50-GTCAAGG (mutated nucleotides underlined) in DRR-P3.4B(Sp1m) (Banks et al., 1998, 1999). The mutated Sp1 site is rendered non-functional (Banks
et al., 1998, 1999). The remaining conventions are as outlined in the legend to Figure 1. Similar results were observed for a minimum of five independent
founder lines for each transgene. It should be noted that although the intensity of signal appears to vary when measured by immunohistology, these signals are
not quantitative, because the extent of peroxidase development varies. Thus, only the involucrin immunoblot signal, after normalization to the b-actin signal,
accurately reflects changes in involucrin level. After scanning and normalization to the b-actin signal in each mouse strain, the level of involucrin in the
DRR-P3.4B animals (five independent founder lines) was 100712 arbitrary units as compared to 2073 arbitrary units in DRR-P3.4B(Sp1m) mice (the F1
generation from five independent founders).
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Role of the hINV PRR segment
We next examined the function of the PRR segment. This
region encodes C/EBP and AP1 (AP1-1) sites that are
important for promoter activity in cultured keratinocytes
(Welter et al., 1995; Agarwal et al., 1999; Eckert et al., 2004).
However, the in vivo role of this region has not been studied.
We therefore mutated the AP1-1 site and/or the C/EBP site to
produce the transgenes shown in Figure 5a. Mutation of the
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Figure 3. DRR truncation analysis –a role for AP1-5/Sp1. (a) The left panel shows schematics of the various hINV transgenes. H6B, the full-length transgene, is
shown at the top, with the DRR and PRR segments identified. Each DRR-derived segment is linked in an identical configuration to hINV minimal promoter,
P3.4B. DRR-P3.4B encodes the full-length (nucleotides 2,473/1,953) DRR segment. The ends of the DRR-derived DNA segment present in each construct are
indicated in nucleotides. The positions of the Sp1, C/EBP, and AP1-1 and AP1-5 sites are indicated. Other conventions are as in the legend to Figure 1. The right
panel indicates the status of transgene expression in esophagus, cervix, epidermis, and footpad. þ þ þ indicates optimal expression, þ indicates reduced
expression,  indicates absence of expression, normal indicates that the transgene is expressed in a differentiation-appropriate manner indistinguishable from
expression of hINV H6B, and high suprabasal indicates that the transgene expression is confined to the high suprabasal layers. Similar results were observed in
each of five independent founder-derived transgenic lines for each transgene. (b) Immunohistological staining of the footpad of hINV DRR truncation construct
transgenic mice. Footpad sections were prepared, stained with anti-hINV and secondary antibody, and visualized as described in Materials and Methods. The
arrow indicates the epidermal basal layer.
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AP1-1 site results in no apparent change from the normal
pattern of expression (Figure 5b). In contrast, mutation of the
C/EBP site (Figure 5c) results in an atypical pattern of
discontinuous expression. This phenotype is also observed
in C/EBPm/AP1-1mm mice (not shown), indicating that the
altered expression is due to the absence of a functional C/EBP
site. This phenotype is observed in footpad and in the other
tested epithelia (Figure 5c).
DISCUSSION
The process and signals that convert a basal cell to a
differentiated surface epithelial cell are not well understood.
Nor are the molecular events that regulate gene expression
during this process. We have attempted to understand this
process by focusing on the mechanisms that regulate
expression of a single gene – involucrin (Eckert et al., 1993,
2004). Involucrin is selectively expressed in the differentiat-
ing suprabasal cells in surface epithelia (Rice and Green,
1979; Banks-Schlegel and Green, 1981). As cells complete
the final stages in terminal differentiation, involucrin is
incorporated via the action of transglutaminase to form part
of the crosslinked protective surface (Rice and Green, 1979;
Yaffe et al., 1992, 1993; Eckert et al., 1993; Nemes et al.,
1999; Nemes and Steinert, 1999).
The hINV promoter DRR
Cell culture-based studies indicate that the AP1-5 site is
required for optimal hINV promoter activity (Welter et al.,
1995; Banks et al., 1998; Bikle et al., 2002). Mutation of this
site, in the context of the full-length hINV promoter, results in
a partial loss of promoter activity, whereas its mutation in the
context of the isolated DRR results in a complete loss of
promoter activity. The finding that simultaneous mutation of
AP1-5 in the DRR and AP1-1 in the PRR results in a near-
complete loss of activity suggested that both these sites have
important functional roles (Welter et al., 1995). A role for the
AP1-5 site has also been confirmed in vivo in mouse footpad,
esophagus, and cervix, where mutation of this site results in a
loss of expression (Crish et al., 2002). Our present studies
confirm these observations and extend these findings to the
epidermis. These findings suggest that the AP1-5 site and AP1
transcription factors play a central role in maintaining hINV
gene expression across a range of surface epithelial tissues. In
contrast, and much to our surprise, mutation of the PRR AP1-1
site causes no change in hINV transgene expression. Thus,
although AP1-1 appears to be functionally important in vitro,
it does not appear to play a major role in vivo. It is possible
that the AP1-1 site is not utilized owing to chromatin-
mediated inaccessibility.
A role for the DRR Sp1 site
Previous studies identified an Sp1 site, located downstream
and adjacent to the AP1-5 site, as being important for optimal
involucrin promoter activity in cultured keratinocytes (Welter
et al., 1995; Banks et al., 1998; Crish et al., 2000). In this
context, it has been suggested that Sp1 proteins may facilitate
AP1 factor loading at the AP1-5 site – this is based on
intracellular transcriptional regulation studies (Banks et al.,
1998). Indeed, our present in vivo studies confirm a role for
the DRR Sp1 site. Its mutation results in a lower level of
transgene expression. Moreover, like AP1-5, this site appears
to be a universal mediator, as mutation of the Sp1 site reduces
hINV expression in all tissues examined, including footpad,
cervix, epidermis, and esophagus. This may be due to an
impact of Sp1 interaction on AP1 factor binding to the
adjacent AP1-5 site, a possibility that has been suggested
(Banks et al., 1998). However, it is interesting that although
the Sp1 site mutation lowers overall expression, the expres-
sion remains differentiation-dependent. It is interesting that
this Sp1 site is absolutely essential for involucrin expression
in the corneal epithelium (Adhikary et al., 2004, 2005).
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Figure 4. Involucrin transgene expression in murine epidermis. Adult mice
were killed, at 3–8 months of age, and the epidermis was collected following
release from the dermis by overnight treatment with dispase at 41C.
(a,b) Extracts were then prepared, electrophoresed on 6% polyacrylamide
gels, and transferred to nitrocellulose for immunoblot with anti-hINV. The
transgene name is indicated on the right of each blot and the number of each
individual transgenic line is indicated above each lane (eg eight hINV H6B
lines were tested). Each line is an independently derived strain and all
animals are from the F1 or subsequent generations. Equivalent loading was
confirmed by stripping the blot and incubating with anti-b-actin (not shown).
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Figure 5. Role of the PRR C/EBP site. (a) hINV transgene structure. The top line shows the full-length H6B transgene. The remaining constructs show
the mutants. The AP1-1, AP1-5, C/EBP, and Sp1 sites are indicated. Other conventions are indicated in the Figure 1 legend. The AP1-1 site sequence,
50-TGAGTCAG, is mutated to 50-AGCTCCAG (mutated nucleotides underlined) in hINV H6B(AP1-1mm). The C/EBP site, 50-GCTGCTTAAGA, is mutated to
50-GCTGAGATCTA (mutated nucleotides underlined) in hINV H6B(C/EBPm). The mutated sites are rendered non-functional (Welter et al., 1995; Agarwal et al.,
1999). Both sites are mutated in H6B(C/EBPm/AP1-1mm). (b, c) Immunoblot and immunohistology for the hINV H6B(AP1-1mm) and hINV H6B(C/EBPm/AP1-
1mm) transgene expression in mouse footpad, cervix, epidermis, and esophagus. The discontinuous pattern of involucrin expression was observed in multiple
tissues of multiple transgenic F1 lines for each construct, including four hINV H6B(C/EBPm) and three hINV H6B(C/EBPm/AP1-1mm) lines.
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The AP1-5/Sp1 element of the DRR
To evaluate the role of the DRR in greater detail, we tested
the ability of DRR subsegments to drive gene expression.
Truncation of the DRR to generate smaller and smaller
segments defines multiple, spatially distinct elements as
required for differentiation-appropriate gene expression.
Removal of nucleotides to position 2,043 results in no
change in expression as compared to the full-length DRR
segment. However, removal of an additional 54 nucleotides
to position 2,097 (Figure 3) results in a reduction in overall
expression level and reduced expression in the immediate
suprabasal layers (Figures 3 and 4). Expression is also reduced
when the hINV AP1-5/Sp1 site-containing segment is tested
in isolation. Moreover, expression is absent in the immediate
suprabasal tissue but maintained in the high suprabasal
layers. In these experiments, we chose to remove the
intervening sequence when creating the DRR constructs.
Although it is possible that this may change the regulatory
properties of this element, we decided that this approach was
preferable to inserting a large segment of spacer DNA, which
may also alter regulation in an unknown manner.
The hINV promoter PRR
Promoter analysis studies in cultured keratinocytes indicate
that the hINV promoter C/EBP and AP1-1 sites, located
immediately upstream of the transcription start site, are
required for promoter activity (Welter et al., 1995; Efimova
et al., 1998; Balasubramanian et al., 2000, 2002; Efimova
and Eckert, 2000; Balasubramanian and Eckert, 2004). In the
present study, we examined the effect of mutating these sites
separately and together. Mutation of the AP1-1 site produces
no apparent change in expression. The most remarkable
change is observed following mutation of the C/EBP site.
These animals display an unusual pattern of intense expres-
sion alternating with reduced or absent expression. This
pattern is observed in all tested surface epithelia, but is
particularly evident in the footpad. In vitro DNA binding
assays, using extracts prepared from cultured keratinocytes,
indicate that the C/EBP site binds C/EBPa (Agarwal et al.,
1999) and that transcription is enhanced by co-transfection of
the hINV promoter with C/EBPa (Agarwal et al., 1999;
Balasubramanian et al., 2000). Finally, the mitogen-activated
protein kinase signaling cascade is known to increase C/EBPa
level and binding to DNA (Efimova et al., 2002). These results
suggest that interfering with C/EBP factor input has dramatic
effects on hINV expression.
A working model of involucrin gene regulation
Based on the available in vivo studies, we propose that the
DRR consists of at least three key regulatory binding sites
(Figure 6). The AP1-5 site is absolutely required for
expression and appears to function as an on/off switch; the
Sp1 site, located adjacent to the AP1-5 site, appears to
function to maximize expression; and a third region, a
putative ISE, appears to be required for expression in the
immediate suprabasal layers (Figure 6). The PRR C/EBP site is
also important, and is required for continuous expression in
all tissues (Figure 6 and Table 1). Based on these findings, we
propose that a transcriptional complex forms on the DRR that
includes JunB, JunD, and Fra-1 at the AP1-5 site, Sp1 at the
Sp1 site, and unknown differentiation-regulatory factors at
the ISE (Welter et al., 1995; Banks et al., 1998), and that
a parallel complex forms over the PRR that includes
C/EBP factors (Welter et al., 1995; Agarwal et al., 1999),
–500–1000–1500–2000–2500
15
hINV Promoter
0
C/EBP (mutation results in a
patchy/discontinuous pattern
of expression)
Sp1 (mutation results in
reduced expression in all
tissues)
AP1-1 (mutation results
in no change in expression
level or pattern of expression)
AP1-5 (mutation results in the
complete loss of expression in
all tissues)
ISE (deletion results in
loss of immediate supra-
basal expression)
DRR
PRR
–2500 0 3330
DRR PRR
Exon 2Exon 1
Figure 6. Spatial distribution and function of key involucrin promoter
regulatory sites. The top line represents the complete involucrin gene –
including the upstream regulatory region (2,500/0) which includes the DRR
and PRR, the transcription start site indicated by the arrow, and non-coding
exon 1 and coding exon 2 (Eckert and Green, 1986; Crish et al., 1998). The
second line shows and expanded involucrin promoter upstream regulatory
region. The arrow indicates the site of transcription initiation. The PRR
(nucleotides 241/7) is indicated by the gray rectangle adjacent to the
transcription start site. The C/EBP and AP1-1 sites are shown within the PRR.
The DRR (nucleotides 2,473/1,953), which contains the AP1-5, Sp1, and
ISE sites, is indicated by the upstream gray rectangle. The impact of mutating
each element on in vivo involucrin promoter activity is indicated.
Table 1. Role of transcription factor binding sites in
the hINV promoter
Transcription
factor binding site Location In vivo function
AP1-5 DRR Mutation results in
complete loss of
expression in all tissues
Sp1 DRR Required for optimal level
of expression, mutation
results in reduced
expression
ISE DRR (immediately 30 of
AP1-5/Sp1 sites)
Required for expression in
early differentiated layers
C/EBP PRR Mutation results in
discontinuous expression
AP1-1 PRR Essential for promoter
activity in cultured
keratinocytes - in vivo
mutation has minimal
impact on expression
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and that ultimately, these factors may come into contact to
fully activate differentiation-appropriate involucrin gene
expression.
MATERIALS AND METHODS
Construction of hINV transgenes and production and identifica-
tion of hINV gene-positive mice
The H6B transgene is a 6 kb HindIII/BamHI fragment containing the
complete hINV gene that was derived by restricting Charon 4AlI-3
with HindIII/BamHI and subcloning the resulting 6 kb fragment into
HindIII/BamHI-restricted pSP64 to yield pSP64lI-3 H6B (Eckert and
Green, 1986). Each of the constructs was derived from this construct
using previously described methods (Crish et al., 1993, 1998, 2002).
For microinjection, the transgenes were released from plasmid
sequences by restriction with HindIII/BamHI. Mouse embryos,
obtained from B6CBAB6CBA mating, were injected with each
individual transgene. The injected embryos were placed into
surrogate mothers (Crish et al., 1993, 1998) and the resulting
offspring were characterized for transgene presence by hINV tail
DNA blotting. The hINV cDNA probe does not crossreact with the
endogenous mouse involucrin gene; thus, the presence of hINV gene
sequences can be directly detected (Crish et al., 1993). A minimum
of three and a maximum of eight individual transgenic founders were
characterized for each transgene tested, and all lines were bred to
the F1 and subsequent generations prior to testing. All the
experiments were approved by the Institutional Animal Care and
Use Committee.
Detection of hINV transgene expression
It is important to note that all of the transgenes utilized in the present
study retain the hINV coding sequence in a native configuration with
respect to the hINV promoter segments. To assay for transgene
expression, we monitored the presence of hINV protein by
immunoblot and by immunohistology. Our antibodies readily
distinguish the hINV protein produced from the transgene from the
endogenous murine involucrin protein (LaCelle et al., 1998). To
detect hINV expression in mouse tissues, total protein extracts were
prepared from epidermal samples following release of the epidermis
with dispase treatment. The samples were then prepared in Laemmli
sample buffer, and equivalent amounts of protein from each sample
were electrophoresed on an acrylamide gel and transferred to
nitrocellulose for antibody-dependent detection of hINV. The blot
was incubated with a primary antibody prepared against recombi-
nant hINV (LaCelle et al., 1998) diluted 1:600 and visualized using a
chemiluminescent detection system (Crish et al., 1993). The blot was
then stripped and incubated for detection of b-actin as a loading
normalization control. For immunohistology, sections were prepared
as previously described (Crish et al., 1993, 1998) and then incubated
with rabbit anti-hINV followed by a peroxidase-conjugated goat
anti-rabbit IgG and visualization by peroxidase substrate deposition.
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